Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Healthcare Biotechnology
Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Sirona Biochem Corp > CYCLIC GLYCOAMINOACID DERIVATIVES
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1168)
•••
Comment by Pandoraon Oct 19, 2023 12:47pm
128 Views
Post# 35691147

RE:RE:RE:CYCLIC GLYCOAMINOACID DERIVATIVES

RE:RE:RE:CYCLIC GLYCOAMINOACID DERIVATIVES
biorun wrote: If you go to the main patent, you can see the relatively long list of country and regional patent filings. The number of markets is impressive. 


It's just sitting in limbo in the USPTO for over a year. Nobody appears to be pushing it.

 
 
 

17/627,347 | REGIM 3.3F-558:

Glycopeptides Increasing Lipid Synthesis

Public view
Application #

17/627,347

Confirmation #

3484

Attorney Docket #

REGIM 3.3F-558

Patent #

-

Filing or 371 (c) date

01/14/2022

Status

Docketed New Case - Ready for Examination 06/21/2022

Application data

Application type

Utility

Examiner

DOCKET CENTRAL

 
Group art unit

OPAP

Class/subclass

424/401.000

AIA (first inventor to file)

Yes

Entity status

Regular Undiscounted

Earliest publication #

US 2022-0267380 A1open_in_new

download

Earliest publication date

08/25/2022

Assignee for publication
  • TFCHEM
    Val De Reuil (FR)
Confirmation #
3484
Intl. registration # (Hague)

-

Intl. registration publication date

-

Correspondence address
530 - Lerner David LLP
 
20 COMMERCE DRIVE
 
CRANFORD, NJ
UNITED STATES
Inventors
  • Graldine Deliencourt-Godefroy
    Sainte Adresse (FR)
  • Jocelyne Legoedec
    Sotteville-Les-Rouen (FR)
  •  
Applicants
  • TFCHEM
    Val De Reuil (FR)

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities